The results of the ROC curves showed that TASL was stronger than approved immunotherapy predictors such as TMB, MSI and PD-L1 in predicting immune score and TIL score, and the AUC values of the ROC curves for TASL to predict the response of cancer patients to immunotherapy ranged from 0.641 to 0.949, indicating that TASL can predict the immune activity of tumors and the efficacy of immunotherapy from some degree of accuracy. The gene discussed is CD274; the disease is cancer.